Lolekha Praween, Khovidhunkit Weerapan, Deerochanawong Chaicharn, Thongtang Nuntakorn, Boonyasirinant Thananya, Rattarasarn Chatchalit, Chutinet Aurauma, Ophascharoensuk Vuddhidej, Somlaw Nicha, Sitthisook Surapun, Suntorntham Surajit, Nitiyanant Wannee, Krittayaphong Rungroj
Department of Medicine, Thammasat University, Patrhumthani 12121, Thailand.
Department of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok 10330, Thailand.
Asian Biomed (Res Rev News). 2024 Dec 16;18(6):246-267. doi: 10.2478/abm-2024-0033. eCollection 2024 Dec.
The Royal College of Physicians of Thailand (RCPT) published a Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease (ASCVD) Prevention in 2016. The availability of newer classes of medications for dyslipidemia, supported by extensive clinical research findings, indicates a significant need for the updating of the existing clinical practice guideline.
To serve as guidelines on the management of dyslipidemia for Thai adults.
The RCPT Dyslipidemia Guidelines Committee was established with representatives from selected professional societies to revise the 2016 Guideline by critically reviewing the latest evidence. Meetings were conducted from August to December 2023, culminating in a public hearing that engaged various stakeholders in January 2024. The final Thai version received approval in April 2024, while the English translation was completed in October 2024.
Lifestyle modifications and statins remain the cornerstone of therapy for dyslipidemia in adults across various clinical settings. Emerging evidence regarding newer classes of lipid-lowering medications indicates that these treatments are effective in lowering LDL-cholesterol levels and reducing atherosclerotic cardiovascular events. This suggests that they may serve as an add-on therapy for individuals who cannot achieve target levels or who are at high risk for future cardiovascular events. The Thai CV Risk Score is recommended due to its specificity for the Thai population.
The 2024 updated clinical practice guidelines establish a framework, provide recommendations, and serve as a comprehensive resource for the contemporary management of dyslipidemia in adults, with the goal of preventing ASCVD in Thailand.
泰国皇家内科医师学会（RCPT）于2016年发布了关于血脂异常药物治疗以预防动脉粥样硬化性心血管疾病（ASCVD）的临床实践指南。新型血脂异常药物的出现，得到了广泛临床研究结果的支持，表明迫切需要更新现有的临床实践指南。
作为泰国成年人血脂异常管理的指南。
成立了RCPT血脂异常指南委员会，成员来自选定的专业协会，通过严格审查最新证据来修订2016年指南。会议于2023年8月至12月举行，最终在2024年1月举行了一次让各利益相关者参与的公开听证会。泰语最终版本于2024年4月获得批准，英文翻译于2024年10月完成。
生活方式改变和他汀类药物仍然是各类临床环境中成人血脂异常治疗的基石。关于新型降脂药物的新证据表明，这些治疗在降低低密度脂蛋白胆固醇水平和减少动脉粥样硬化性心血管事件方面是有效的。这表明它们可能作为无法达到目标水平或未来心血管事件风险高的个体的附加治疗。由于泰国心血管风险评分对泰国人群具有特异性，因此推荐使用。
2024年更新的临床实践指南建立了一个框架，提供了建议，并作为成人血脂异常当代管理的综合资源，目标是在泰国预防ASCVD。
